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Dyskinesia, a major complication of treatment of Parkinson’s disease (PD), involves two phases: induction, which is responsible
for dyskinesia onset, and expression, which underlies its clinical manifestation. The unique cellular and regional distribution
of adenosine A2A receptors in basal ganglia areas that are richly innervated by dopamine, and their antagonistic role towards
dopamine receptor stimulation, have positioned A2A receptor antagonists as an attractive nondopaminergic target to improve the
motor deficits that characterize PD. In this paper, we describe the biochemical characteristics of A2A receptors and the eﬀects of
adenosine A2A antagonists in rodent and primate models of PD on L-DOPA-induced dyskinesia, together with relevant biomarker
studies. We also review clinical trials of A2A antagonists as adjuncts to L-DOPA in PD patients with motor fluctuations. These
studies have generally demonstrated that the addition of an A2A antagonist to a stable L-DOPA regimen reduces OFF time and
mildly increases dyskinesia. However, limited clinical data suggest that the addition of an A2A antagonist along with a reduction of
L-DOPAmightmaintain anti-Parkinsonian benefit and reduce dyskinesia.Whether A2A antagonists might reduce the development
of dyskinesia has not yet been tested clinically.
1. Adenosine A2A Receptor
Localization and Biochemistry
Adenosine A2A receptors are present in medium to high
concentrations in several basal ganglia (BG) nuclei and may
therefore be capable of influencing motor activity by acting
at diﬀerent BG levels. This feature renders A2A receptors
particularly attractive for modulation of dopamine receptor
functions in a disease such as Parkinson’s disease (PD), which
is caused by degeneration of dopaminergic neurons in the
nigrostriatal pathway, but associated with changes at several
receptor levels. An interesting peculiarity of A2A receptors
is their selective localization in the indirect striatonigral
GABAergic pathway, which contains enkephalin (ENK) and
which is known to lead to inhibition ofmotor behavior [1, 2].
A2A receptors are positively coupled to adenylate cyclase
and, either at the level of second messengers or through
the formation of receptor heterodimers, negatively influence
dopamine D2 receptor activity [3–6]. On the basis of this
anatomical and functional organization, A2A receptors acting
in concert with D2 and D1 receptors are capable of aﬀecting
planning and execution of movements [7, 8]. Moreover,
the low levels of A2A receptors expressed in brain areas
other than the BG are at the basis of the low incidence
of nonmotor side eﬀects observed in clinical trials so far
performed [9]. A2A receptors, however, are expressed in some
peripheral organs and blood cells, underlying the importance
of evaluating these elements in clinical trials testing the
eﬃcacy of A2A receptor antagonists in PD [10, 11].
Interestingly, an abnormal increase in A2A signaling, in
the striatum of 6-hydroxydopamine- (6-OHDA-) lesioned
rats, and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
(MPTP-) treated primates, as well as in PD patients chron-
ically treated with L-DOPA [12–14], might produce a pre-
vailing tone of A2A receptors, the activation of which inhibits
motor activity. Therefore, blockade of the A2A receptor
inhibitory tone could be one of the factors underlying the
positive eﬀects produced by A2A antagonists in PD.
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2. Adenosine A2A Receptor Antagonists in
Animal Models of Dyskinesia
2.1. Behavioral Studies. Preclinical behavioral investigations
suggest that A2A antagonists may be of interest in the man-
agement of dyskinesia in PD. The first preclinical evidence
suggesting that A2A antagonists may be utilized in patients
rendered dyskinetic by L-DOPA was obtained in 6-OHDA
unilaterally lesioned rats subchronically treated with L-
DOPA [17]. In this paradigm, the repeated administration
of L-DOPA causes a progressive, sensitized, increase in con-
traversive turning behavior, which is thought to reproduce
some aspects of the abnormal motor responses induced by
the prolonged treatment with L-DOPA [17–19]. Of great
interest, sensitization in contraversive turning behavior did
not take place when L-DOPA was administered at a low dose
in association with an A2A antagonist [17, 20]. Subsequent
studies utilizing a full eﬀective L-DOPA dose in rats with
established dyskinesia [21] did not report any benefit, since
L-DOPA treatment alone or in combination with an A2A
antagonist presented the same degree of dyskinesia. These
results demonstrated that A2A antagonists are not antidysk-
inetic drugs; however, in this model, they did not worsen
existing dyskinesia while increasing the eﬃcacy of L-DOPA
on motor symptoms.
Studies in MPTP-treated primates, the best experimental
model of PD and PD-associated dyskinesia, have confirmed
the beneficial eﬀects of blockade of A2A receptors. A2A antag-
onists were found not to be prodyskinetic drugs, since their
administration to Parkinsonian primates with established
dyskinesia induced by L-DOPA relieved motor impairment
and did not worsen dyskinesia [22–24]. Moreover, an atten-
uation of dyskinesia induced by long-term apomorphine was
observed when the drug was administered in combination
with an A2A antagonist [25], suggesting that A2A antag-
onists might lower the dyskinetic potential of dopamine-
replacement therapy in specific conditions. The previous
coadministration of an A2A antagonist was also found to
delay the onset of severe dyskinesia when the same primates
were maintained on apomorphine alone [25].
2.2. Biochemical Studies. Regarding the mechanisms under-
lying dyskinesia and the eﬀects of A2A antagonists in exper-
imental models of dyskinesia, it seems likely that these
drugs interfere with the neuroplastic changes induced by
dopamine-replacement therapy in the dopamine-denervated
BG (Figure 1). Studies in 6-OHDA-lesioned rats demonstrate
that striatal dopamine denervation is associated with persis-
tent modifications in the levels of the neuropeptides dynor-
phin (DYN) and ENK, as well as the enzyme glutamic acid
decarboxylase 67 (GAD-67) [21, 26–28] (Figure 1). More-
over, it was observed that chronic treatment with L-DOPA,
which induces a dyskinetic-like motor response, further con-
tributes to these biochemical changes [21, 26, 27] (Figure 1).
Importantly, the coadministration of an A2A antagonist,
besides resulting in a stable motor response, attenuated the
eﬀects of chronic L-DOPA treatment on ENK and GAD-
67 [21, 26, 27]. It has to be acknowledged that, as of
today, no evidence supports a direct role of DYN, ENK,
and GAD-67 in dyskinesia. Nevertheless, changes in the
expression of neuropeptides are a marker of the activity of
striatal neurons [26]. Therefore, it can be suggested that A2A
antagonists modulate the eﬀects of L-DOPA and mitigate the
neuroplastic changes this drug induces in the striatum. These
eﬀects could arise from the opposite functional interactions
involving adenosine A2A and dopamine D1 and D2 receptors
[29]. These interactions, by amplifying dopaminergic signal-
ing, would regulate the activity of striatal output neurons in
conditions of dopamine denervation and nonphysiological
stimulation of dopamine receptors (Figure 1).
It has to be considered that A2A receptor antagonists,
in addition to their potential eﬀects on biochemical and
functional changes induced by dopamine-replacement ther-
apy, potentiate the motor-activating eﬀects of L-DOPA and
dopaminergic agonists, allowing their use at lower, nondysk-
inetic doses [7]. Hence, the sparing of dopaminomimetic
drugs in combination with an A2A antagonist may contribute
to the attenuation, or delay, of the maladaptive modifications
in striatal function which underlie dyskinesia.
2.3. Role of Glutamate Transmission. Besides the facilitation
of dopamine transmission, other mechanisms have been
proposed to underlie, or at least participate in, the eﬀects of
A2A receptor antagonists observed in experimental models
of dyskinesia. Neuroanatomical studies demonstrate that
striatal A2A receptors are highly expressed at the postsynaptic
level in asymmetric synapses, where they can interact with
glutamate receptors [30]. Glutamate receptors are thought
to participate in the pathophysiology of dyskinesia [31]
and, interestingly, chronic administration of L-DOPA to
6-OHDA-lesioned rats was reported to induce a hyper-
phosphorylation state of the α-amino-3-hydroxy-5-methyl-
4-isoxazole-propionic acid (AMPA) receptor [25, 32]. This
eﬀect was found to be significantly attenuated when L-DOPA
was administered in combination with an A2A antagonist [25,
32]. Evidence also exists that A2A receptors may regulate the
conductance of N-methyl-D-aspartate (NMDA) receptors
[33]. This may have important implications for dyskinesia,
since NMDA receptors play a major role in neuroplasticity
phenomena [34, 35], including those which take place in
motor circuits, and may underlie abnormal motor responses
to dopamine-replacement therapy used in PD.
Interactions between A2A receptors and type 5 metabo-
tropic glutamate receptors (mGlu5) have also been reported
[36–38]. In the light of the evidence showing that antago-
nism of mGlu5 receptors may reduce dyskinesia in MPTP-
lesioned primates treated with L-DOPA [39], it is possible
to envision that combined antagonism on the two receptors
might contribute to the beneficial eﬀects of A2A antagonists
on dyskinesia. Additional mechanisms involved in themodu-
lation of therapy-induced abnormal motor responses by A2A
antagonists could include interaction with nondopaminergic
and nonglutamatergic receptors, such as cannabinoid and
serotonin receptors, and regulation of neurotransmitter
release [40–42]. In this regard, it has to be recalled that A2A
receptors powerfully modulate extracellular concentrations
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Figure 1: Role of A2A receptors on modifications in the activity of the striatal eﬀerent pathways. Under physiological conditions (a), striatal
neurons receive dopaminergic inputs from the substantia nigra pars compacta (SNc). Endogenous dopamine (DA) activates the neurons
belonging to the so-called direct pathway (in green), which send GABAergic projections to the substantia nigra pars reticulata/globus pallidus
pars interna (SNr/GPi) and express D1 stimulatory dopamine receptors, together with the neuropeptide dynorphin (dyn). At the same time,
dopamine also depresses the neurons belonging to the so-called indirect pathway (in red) which send GABAergic projections to the SNr/GPi
via globus pallidus pars externa (GPe) and subthalamic nucleus (STN) and express D2 inhibitory dopamine receptors and the neuropeptide
enkephalin (enk). Adenosine A2A receptors stimulate the indirect pathway where they are selectively expressed, and their activation negatively
modulates the function of D2 receptors. A balanced level of activity of the direct and indirect pathways is at the basis of the correct processing
of motor information andmovement execution. In Parkinson’s disease (b), the degeneration of the neurons located in the SNc leads to a drop
in the dopaminergic input to the striatum. This results in a reduced activation of the direct pathway and in a disinhibition of the indirect
pathway, which is associated with the elevation of A2A receptor transmission. Such unbalanced activity of the striatal output pathways is at
the basis of the motor impairment observed in Parkinson’s disease (b). Administration of L-DOPA restores the compromised dopaminergic
tone since it stimulates the direct pathway and inhibits the indirect one (not shown). However, chronic treatment with L-DOPA (c) leads
to the overactivation of the direct pathway, which together with the increase of A2A receptor activity [12, 15, 16] and enhanced indirect
pathway transmission is at the basis of L-DOPA-induced dyskinesia and loss of eﬃcacy. The addition of an A2A antagonist to L-DOPA (d)
although not counteracting the overactivity of the direct pathway (dyskinesia) stabilizes the activity of the indirect pathway, resulting in
motor stimulation, potentially without a worsening of dyskinesia.
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of glutamate [43, 44], the excessive increase of which plays a
role in the abnormal functioning of BG existing in PD and in
neuroplasticity phenomena.
3. Biomarkers and Neuroimaging Studies
Involving the A2A Receptor
A crucial need in the translation from preclinical studies
to clinical trials is the availability of reliable biomarkers,
which would give the opportunity of monitoring the eﬀects
of the compound on its biological target—the adenosine
receptor—in addition to evaluating its clinical eﬃcacy. In
this field, substantial contributions have been made by
neuroimaging studies, while biological findings in peripheral
tissues have opened interesting perspectives.
3.1. Neuroimaging Studies in Humans. Neuroimaging tech-
niques, based on positron emission tomography (PET), have
been recently used to analyze A2A receptor distribution in the
human brain, either in normal subjects or in PD patients
exposed to L-DOPA; in this latter case, the purpose was to
draw potential in vivo correlations between changes in A2A
receptor availability and the presence of L-DOPA-induced
dyskinesias.
In 2007, Mishina et al. examined the distribution of
A2A receptors in the brain of 5 normal subjects using PET
tracer [7-methyl-11C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-
trimethylxanthine ([11C]TMSX) [45]. Various brain regions
were examined, including the cerebellum, brainstem, thal-
amus, head of caudate nucleus, anterior and posterior puta-
men, frontal lobe, temporal lobe, parietal lobe, occipital lobe,
and posterior cingulate gyrus. Results showed the highest
levels of A2A receptor binding in the putamen, followed by
the caudate nucleus and thalamus, while the lowest levels
were detected in the cerebral cortex. Using a diﬀerent A2A
receptor-specific radiotracer, [11C]SCH442416, Brooks et al.
assessed binding of vipadenant (3-(4-amino-3-methylbenz-
yl)-7-(2-furyl)-3H-[1, 2, 3]triazolo[4, 5-d]pyri-midine-5-
amine), a selective nonxanthine A2A receptor antagonist
synthesized by Vernalis Plc (also known as BIIB014 or
V2006) [15]. Displacement of the PET tracer by increasing
doses of vipadenant (2.5–100mg/day for 10 or 11 days) was
investigated in various brain regions—including the puta-
men, caudate nucleus, nucleus accumbens, thalamus of both
hemispheres, and cerebellum—of 15 healthy volunteers. The
estimated receptor occupancy of vipadenant in the brain
varied from 74% to 94% at the lowest daily dose (2.5mg),
with the highest value being observed in the putamen and
the lowest value in the cerebellum. Saturation was reached
in all regions at the highest dose administered (100mg). It is
noteworthy that double-blind, placebo-controlled, phase 2
clinical trials with vipadenant have been conducted in PD
patients, showing modest anti-PD activity, until a review
of preclinical toxicology studies, conducted by Vernalis Plc,
led to discontinuation of this drug in July 2010 (http://
www.vernalis.com/media-centre/latest-releases/2010-releas-
es/584/).
Recently, Mishina et al., using PET with [11C]TMSX,
measured the binding ability of striatal A2A receptors in 9
untreated PD patients, 7 PD patients with dyskinesia, and
6 age-matched control subjects [16]. They found that the
distribution volume ratio of A2A receptors in the putamen
was larger in patients with L-DOPA-induced dyskinesias than
in control subjects and that L-DOPA treatment tended to
increase the presence of A2A receptors in the putamen.
Further information on the relationship between A2A
receptors and L-DOPA-induced dyskinesias has been pro-
vided by Ramlackhansingh et al., who investigated adenosine
A2A receptor availability in the caudate and putamen of
PD patients with (n = 6) and without L-DOPA-induced
dyskinesias (n = 6) and in age-matched healthy controls
(n = 6) [46]. In line with previous studies [12], they found
that A2A receptor binding was higher in the caudate and
putamen of PD patients with L-DOPA-induced dyskinesias,
with respect to both PD patients without L-DOPA-induced
dyskinesias and controls, thereby lending further support
to the view that A2A antagonists may prove beneficial in
the management of motor complications associated with L-
DOPA treatment. It is worth mentioning that although their
cohort was small and the power was probably too limited
to detect a diﬀerence, Ramlackhansingh et al. did not find
a correlation between striatal [11C]SCH442416 uptake and
dyskinesia severity.
An additional study tested the hypothesis that blockade
of striatal A2A receptors, caused by the selective antago-
nist SYN115, a benzothiazole derivative, may reduce the
inhibitory output of the striatofugal indirect pathway [47].
For this purpose, the authors used a perfusion magnetic res-
onance imaging (MRI) technique, which gives a functional
measure of the cerebral blood flow (CBF) reflecting neu-
ronal activity. The study was conducted during a random-
ized, double-blind, placebo-controlled, crossover study with
SYN115 in 21 PD patients on L-DOPA. The results showed
that SYN115 produced a dose-dependent decrease in thala-
mic CBF, which the authors deemed consistent with reduced
pallid-thalamic inhibition via the indirect pathway [47].
3.2. Peripheral Expression of Adenosine Receptors. To our
knowledge, only one paper has reported the characterization
of adenosine receptors in peripheral tissues (peripheral
blood cells) of human Parkinsonian subjects [48]. In this
study, Varani et al. investigated aﬃnity and density of A1,
A2A, A2B, and A3A receptors in lymphocyte and neutrophil
membranes from PD patients and healthy control subjects;
they also analyzed A2A receptors density in autoptic samples
of putamen from PD patients and control subjects. They
found that A2A receptors were significantly diﬀerent between
PD patients and controls, in terms of aﬃnity and density,
while no changes seemed to aﬀect A1, A2B, or A3A receptors.
In particular, increased density of A2A receptors, coupled
with decreased aﬃnity, was detected in lymphocyte and neu-
trophil membranes of PD patients, with respect to control
subjects. This finding was associated with a reduction in the
mRNA of A2A receptors, while no changes were observed
in the mRNAs of the other adenosine receptor subtypes
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investigated. The postmortem study confirmed this result,
showing increased A2A receptor density in the putamen of
PD patients [48].
4. Clinical Trials of A2A Receptor Antagonists
4.1. Istradefylline. Clinical trials of A2A antagonists in pa-
tients with motor complications have focused on reductions
in OFF time rather than changes in dyskinesia. Istradefylline
was the first A2A receptor antagonist to enter clinical trials
seeking an indication in PD. Bara-Jimenez et al. conducted
an early proof-of-principle study using intravenous L-DOPA
infusions in 15 moderate to advanced PD patients with
motor fluctuations, 6 of whom had L-DOPA-induced peak-
dose dyskinesia [49]. Twelve subjects were randomized to
istradefylline, 3 to placebo, and 1 dropped out. Istradefylline
40 or 80mg had no eﬀect on Parkinsonian signs or dyskinesia
when added to an optimal L-DOPA infusion. However, when
added to a low-dose L-DOPA infusion, istradefylline 40mg
improved Unified Parkinson’s Disease Rating Scale (UPDRS)
motor scores by 24% (P < 0.05) and istradefylline 80mg
improved motor scores by 36% (P < 0.05). The anti-
Parkinsonian response to a low-dose L-DOPA infusion plus
istradefylline 80mg was similar to an optimal-dose L-DOPA
infusion. Notably, the severity of dyskinesia with a low-dose
L-DOPA infusion plus istradefylline 80mg was 45% less (P <
0.05) than with an optimal-dose L-DOPA infusion. This sug-
gests that by lowering the L-DOPA dose and adding istrade-
fylline, one might be able to maintain anti-Parkinsonian
benefit and reduce dyskinesia, a paradigm that has not been
studied in clinical trials using oral L-DOPA preparations.
Istradefylline was then studied in a 12-week, randomized,
placebo-controlled exploratory trial in which patients with
both motor fluctuations and dyskinesia were randomized
to the addition of placebo (n = 29), istradefylline in
ascending doses up to 20mg/day (n = 26), or istradefylline
in ascending doses up to 40mg/day (n = 28) [50]. Anti-
Parkinsonian medications were kept unchanged except that
the total daily L-DOPA dose could be reduced, if necessary, to
ameliorate L-DOPA-related adverse events. Over the course
of the study, there were no significant changes in daily L-
DOPA doses comparing istradefylline and placebo groups
(P = 0.96). Diary results showed that the combined
istradefylline groups experienced a reduction in OFF time
of 1.2 hours, whereas the placebo group experienced an
increase in OFF time of 0.5 hours (P < 0.004). Multiple
assessments of change in dyskinesia did not demonstrate
significant diﬀerences between the placebo and istradefylline
groups, including Goetz dyskinesia scale scores (−0.2 versus
−0.1, P = 0.3), Parkinson dyskinesia scale scores (−1.4
versus −1.3, P = 0.9), and UPDRS items 32–34 (−0.03
versus −0.4, P = 0.8). However, diary results indicated that
ON time with dyskinesia was significantly more increased
with istradefylline than placebo (0.6 hours versus−1.5 hours,
P = 0.001). Troublesome dyskinesia was not included as a
diary category in this study. As an adverse event, increased
dyskinesia was reported by 13.8% of placebo patients and
16.7% of istradefylline patients.
This is an important study in that it is the largest study
of an A2A receptor antagonist in a population of patients,
all of whom have L-DOPA-induced dyskinesia. In addition,
dyskinesia was most thoroughly assessed by multiple scales.
Clearly, the addition of istradefylline to a stable antiparkin-
son regimen did not reduce dyskinesia, nor was there a very
substantial increase. Perhaps the most parsimonious inter-
pretation is that overall severity of dyskinesia was essentially
unchanged, but much or all of the reduction in OFF time was
replaced by an increase in ON time with dyskinesia.
Subsequent trials in moderate to advanced PD patients
all included subjects with motor fluctuations, some of whom
had dyskinesia and some of whom did not. These included
two phase 2 istradefylline trials. In one, istradefylline
40mg/day reduced OFF time compared with placebo by 1.2
hours (P = 0.005) [51]. ON time with dyskinesia increased
by 1.0 hour more in the istradefylline group than the placebo
group (P = 0.035). Of this diﬀerential increase in ON
time with dyskinesia, approximately 0.8 hours were ON time
with nontroublesome dyskinesia (P = 0.065), and 0.2 hours
were ON time with troublesome dyskinesia (P = 0.347).
Dyskinesia was reported as an adverse event in 15.2% of
placebo subjects and 30.2% of istradefylline subjects. In the
other phase 2 study [52], istradefylline 20mg/day reduced
OFF time by 0.64 hours, and istradefylline 60mg/day
reduced OFF time by 0.77 hours (overall P value = 0.065).
Compared with placebo, istradefylline 20mg/day increased
ON time with dyskinesia by 0.54 hours, and ON time
with troublesome dyskinesia by 0.06 hours; istradefylline
60mg/day increased ON time with dyskinesia by 0.23 hours
and ON time with troublesome dyskinesia by 0.04 hours.
Dyskinesia was reported as an adverse event in 14.3% of
placebo subjects, 23.9% of istradefylline 20mg/day subjects,
and 22.6% of istradefylline 60mg/day subjects.
In a phase 3 study, istradefylline 20mg/day reduced OFF
time compared with placebo 0.7 hours (P = 0.03) [53].
Increases in dyskinesia were similar in placebo and istrade-
fylline groups (ON time with dyskinesia: 0.5 versus 0.7 hours,
P = 0.57; ON time with nontroublesome dyskinesia: 0.4
versus 0.4 hours, P = 0.82; ON time with troublesome dysk-
inesia: 0.2 versus 0.3 hours, P = 0.48). However, dyskinesia
was reported as an adverse event in 22.6% of istradefylline
subjects compared with 12.2% of placebo subjects.
In a phase 3 study in Japan [54], istradefylline 20mg/day
reduced OFF time compared with placebo by 0.65 hours
(P = 0.013) and 40mg reduced OFF time compared with
placebo by 0.92 hours (P < 0.001). Compared with placebo,
istradefylline 40mg/day significantly increased ON time with
troublesome dyskinesia (0.35 hours, P = 0.011). As an
adverse event, dyskinesia was reported in 2.5% of placebo
subjects, 8.5% of istradefylline 20mg/day subjects, and 6.4%
of istradefylline 40mg/day subjects.
Thus, in most of the clinical trials, the addition of istra-
defylline was associated with some increase in ON time
with dyskinesia, and dyskinesia was reported as an adverse
event more commonly in istradefylline- than placebo-treated
subjects.
A recent population pharmacokinetic-pharmacodyna-
mic study analyzed data from 1798 patients participating in
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6 phase 2/3 istradefylline trials [55]. The analysis predicted
a maximum probability of experiencing dyskinesia as an
adverse event sometime during a study as 15.4% for placebo,
22.5% for istradefylline 20mg/day, 24.1% for istradefylline
40mg/day, and 24.3% for istradefylline 60mg/day.
Thus, clinical data to date do not provide evidence for
an antidyskinetic eﬀect of istradefylline but rather suggest
that istradefylline mildly increases dyskinesia in a dose-
dependent fashion. Results vary slightly from trial to trial and
may depend, in part, on the percentage of subjects with dysk-
inesia at baseline and the severity of their dyskinesia. Other
potential factors may include concomitant medications such
as amantadine and dietary intake of caﬀeine, a nonspecific
adenosine antagonist, although these factors have not been
systematically evaluated.
4.2. Preladenant. Preladenant was evaluated in a phase 2, 12-
week, dose-finding study of PD patients experiencing motor
fluctuations [56]. In this study, patients were randomized to
preladenant 1, 2, 5, or 10mg twice daily (BID) or matching
placebo. OFF time was significantly reduced compared with
placebo in subjects randomized to preladenant 5mg BID (1.0
hours, P = 0.0486) and preladenant 10mg BID (1.2 hours, P
= 0.019). In the 5mg BID group, compared with placebo, ON
time with dyskinesia was increased 0.9 hours (P = 0.185), ON
time with nontroublesome dyskinesia was increased by 1.0
hour (P = 0.064), and ON time with troublesome dyskinesia
was decreased by 0.1 hours (P = 0.812). In the preladenant
10mg BID group, compared with placebo, ON time with
dyskinesia was increased by 1.3 hours (P = 0.054), ON
time with nontroublesome dyskinesia was increased by 1.1
hours (P = 0.047), and ON time with troublesome dyskinesia
was increased by 0.2 hours (P = 0.540). These results
appear to be similar to some of the istradefylline findings in
which much of the reduction in OFF time was replaced by
ON time with nontroublesome dyskinesia. Dyskinesia was
reported as an adverse event by 13% of placebo subjects,
by 9% of preladenant 5mg BID subjects, and by 13% of
preladenant 10mg BID subjects. This result may be diﬀerent
from what has been observed with istradefylline where
dyskinesia was rather consistently reported more frequently
as an adverse event in istradefylline-compared with placebo-
treated groups. Thus, preliminary results suggest that like
istradefylline, preladenant does not reduce dyskinesia, but
it remains to be seen whether preladenant causes less dysk-
inesia than istradefylline, as suggested by these adverse event
results.
To our knowledge, there have been no clinical trials
evaluating whether an A2A receptor antagonist can reduce
the development of dyskinesia when administered in early
disease concomitant with the introduction of dopaminergic
therapy. Based on animal model data, this remains an impor-
tant avenue for future investigation. Similarly, we are not
aware of clinical trials of patients with L-DOPA-induced
dyskinesia to determine whether lowering the L-DOPA dose
and adding an A2A receptor antagonist will allow mainte-
nance of the anti-Parkinsonian response with reduction of
dyskinesia.
5. Conclusions
The management of PD is most complex in the treatment
of late, complicated PD, when the response to L-DOPA is
associated with dyskinesia. From the studies described in
the present paper, it is suggested that the management of
the first (uncomplicated) phase has important consequences
on the induction of dyskinesia that characterize the second
(complicated) phase.
Preclinical studies suggest that A2A antagonists might
reduce the development of dyskinesia, but this has not yet
been tested clinically. In PD patients, once dyskinesias are
established, adding an A2A antagonist to a stable dopamin-
ergic therapeutic regimen does not appear to provide an
antidyskinetic response, and most clinical trials have sug-
gested a mild increase in dyskinesia in association with a
reduction in OFF time. Limited clinical data suggest the pos-
sibility that in PD patients with established dyskinesia, one
might be able to maintain the anti-Parkinsonian response
and reduce dyskinesia by adding an A2A antagonist and low-
ering the L-DOPA dose, but this remains to be proven. Thus,
critical aspects of the potential benefits of A2A antagonists
with regard to dyskinesia are yet to be evaluated.
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